+

WO2007016953A1 - Composition for reducing alcohol induced liver cancer risk - Google Patents

Composition for reducing alcohol induced liver cancer risk Download PDF

Info

Publication number
WO2007016953A1
WO2007016953A1 PCT/EP2005/009151 EP2005009151W WO2007016953A1 WO 2007016953 A1 WO2007016953 A1 WO 2007016953A1 EP 2005009151 W EP2005009151 W EP 2005009151W WO 2007016953 A1 WO2007016953 A1 WO 2007016953A1
Authority
WO
WIPO (PCT)
Prior art keywords
food composition
dietary supplementation
dose
alcohol
supplementation according
Prior art date
Application number
PCT/EP2005/009151
Other languages
French (fr)
Inventor
Markus Graf V. Matuschka-Greiffenclau
Original Assignee
Matuschka-Greiffenclau Markus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matuschka-Greiffenclau Markus filed Critical Matuschka-Greiffenclau Markus
Priority to DK06762860.2T priority Critical patent/DK1909600T3/en
Priority to AT06762860T priority patent/ATE554663T1/en
Priority to PCT/EP2006/007466 priority patent/WO2007017139A1/en
Priority to AU2006278823A priority patent/AU2006278823B2/en
Priority to EP06762860A priority patent/EP1909600B1/en
Priority to CA2611389A priority patent/CA2611389C/en
Priority to ES06762860T priority patent/ES2386460T3/en
Priority to KR20137031344A priority patent/KR101487848B1/en
Priority to US11/997,127 priority patent/US8580750B2/en
Priority to JP2008523251A priority patent/JP5371428B2/en
Priority to KR1020077028054A priority patent/KR101562271B1/en
Priority to UAA200800602A priority patent/UA94713C2/en
Priority to PL06762860T priority patent/PL1909600T3/en
Priority to EA200800427A priority patent/EA012753B1/en
Priority to PT06762860T priority patent/PT1909600E/en
Priority to SI200631337T priority patent/SI1909600T1/en
Publication of WO2007016953A1 publication Critical patent/WO2007016953A1/en
Priority to HK08110628.1A priority patent/HK1117709A1/en
Priority to HRP20120489TT priority patent/HRP20120489T1/en
Priority to JP2013091972A priority patent/JP5785581B2/en
Priority to US14/058,388 priority patent/US9402849B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention is directed to a composition, in particular a food composition, or dietary supplementation, which is active in respect to a reduction of alcohol or drug induced liver cancer rise.
  • the invention is directed to a composition affecting the moderation of a drug, in particular alcohol degradation process within the human body.
  • an object of the present invention is to achieve solutions which provide a reduction in the toxic effects or physiological stress in connection with the consumption of drugs, in particular alcohol, in particular for people with a predisposition towards rapid alcohol degradation and subsequent accumulation of acetaldehyde due to a genetic polymorphism of human acetaldehyde-dehydrogenase enzym.
  • Ethanol taken into the body is eliminated by its oxidation mainly in the liver.
  • Ethanol is first metabolised to acetaldehyde by alcohol dehydrogenase (ADH), and then acetaldehyde is further metabolised to acetic acid by aldehyde dehydrogenase (ALDH).
  • ADH alcohol dehydrogenase
  • ALDH aldehyde dehydrogenase
  • the first metabolite of orally ingested alcohol, acetaldehyde is suspected to play a pivotal role in the development of alcohol related cancers because of its established DNA damaging effects (single-strand and double-strand breaks) and carcinogenicity in laboratory animals.
  • acetaldehyde can damage the culture hepatocytes and results in secondary hyperproliferation .
  • ALDH2 class 2 ALDH
  • a mutant allele ALDH2*2 has a single point mutation (G- »A) in exon 12 of the active ALDH2*1 gene. This mutation is expected to result in a substitution of glutamic acid (GIu) at amino acid position 487 by lysine (Lys), acting in a dominant negative fashion. This mutation is confined to Orientals. Acetaldehyde oxidation is strikingly impaired in individuals with ALDH2*2 allele. ALDH2 deficiency is associated with increased the risk of cancer of the oral cavity, pharynx, larynx and esophagus.
  • Hepatitis viruses are known to increase the risk of liver cancer.
  • Epidemiological surveys are considered to support that ALDH2 deficiency is associated with increased the risk of liver cancer of alcohol drinkers with or without hepatitis viruses.
  • Our supplement mix accelerates the metabolism of alcohol and acetaldehyde. This mixture decreases the concentration of blood acetaldehyde after drinking. Therefore, our supplement is expected to decrease the risk of liver cancer for alcohol drinkers, especially those who have ALDH2*2 allele.
  • the present invention particularly solves the problem of a long impact of an accumulation of acetaldehyde after rapid alcohol degradation i.e. alcohol metabolism as may occur in most people of Non-Caucasian type genetic structure.
  • the particular food composition or dietary supplementation is considered to be appropriate to reduce a peak of excess acetaldehyde entering the blood stream and is intended to lower the risk of damage to vital organs and functions of the human body, and in this connection also lowers the risk of liver cancer.
  • the niacin-fraction (Vitamin B3) included in the composition functions as nicotinamide adenine dinucleotide (NAD), which is effective towards a coenzyme to alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).
  • NAD nicotinamide adenine dinucleotide
  • ADH alcohol dehydrogenase
  • ADH alcohol dehydrogenase
  • ADH aldehyde dehydrogenase
  • the composition also includes Pantotheic acid.
  • Pantotheic acid functions as coenzyme A (CoA), which is considered necessary to metabolize acetic acid.
  • Acetic acid is activated in conjugation with CoA to form acetyl-CoA, which is metabolized in TCA cycle.
  • elimination of a product (acetic acid) is effective towards an acceleration of the metabolism of a substrate (acetaldehyde).
  • this food composition or supplements should be taken about 5 minutes prior to consumption of alcohol and in case of high alcohol consumption again whilst consuming alcohol.
  • the mass of the food composition taken by the consumer should be in the range of about 70 to 120% of the mass of the alcohol included in the consumed drinks.
  • a standard dose might include about 10. Og dextrose, 1.Og Vitamin C, 1.5g L-glutamine, 500mg cysteine, 40mg riboflavin, 100 mg succinic acid, 100 mg fumaric acid, 60mg coenzyme QlO, and about 10 mg Niacin (Vitamin B3).
  • the relation of the components of the composition is oriented towards the above given relation.
  • the overall dosage may be adapted to the body mass weight of the consumer.
  • the particular food composition, or dietary supplementation is intended to prevent too much acetaldehyde passing into the mitochondrial matrix and to suppress self- blockade of the enzymatic activity of ALDH and thus facilitate its the decomposition of acetaldehyde.
  • the physiological risks in connection with alcohol consumption may therefore be significantly reduced by the use of the food composition according to the present invention, as this food composition or dietary supplementation facilitates in a synergetic manner an early decrease of the level of acetaldehyde after drinking and simultaneously provides a protective effect in respect of the suppression of the generation of free radicals.
  • Said food composition or dietary supplementation is preferably in such a form, preferably as ingredients of a kind of aperitif, that it allows the food composition to be consumed within a restaurant or a bar prior to consuming alcoholic drinks.
  • a dosage for a person with a body weight of about 80 kg includes a dextrose fraction of approx. 75%, wherein the said dosage may have an overall weight of about 10 to 15, preferably 13.3g.
  • Such a dosage is to provide a considerable moderation in degrading about 18ml alcohol.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same, includes a dextrose fraction of about 75.2 mass%, i.e. a quantity of dextrose in the range from 7.2 to 12.8g, preferably 10.0 g within a dose of 13,3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a Vitamin C fraction of about 7.5 mass% i.e a quantity of Vitamin C in the range from 0.78 to 1.18 g, preferably 1.Og, within a dose of 13.3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a L-glutamine fraction of about 11.27 mass%, i.e. a quantity of said L-glutamine fraction in the range from 1.23 to 1.7 g, preferably 1.5g, within a dose of 13.3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a cysteine fraction of about 3.76 mass%, i.e. a quantity of said cysteine fraction in the range from 460 to 540 mg, preferably 500mg, within a dose of 13.3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a riboflavin fraction of about 0.30 mass% i.e. a quantity of said riboflavin in the range from 32 to 48 mg, preferably 40mg, within a dose of 13.3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a succinic acid (Bernsteinsaure) fraction of about 0.752 mass%, i.e. a quantity of said succinic acid in the range from 90 to 1 10 mg, preferably lOOmg, within a dose of 133g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a fumaric acid (Fumarsaure) fraction of about 0.752 mass%, i.e. a quantity of said fumaric acid in the range from 90 to 110 mg, preferably lOOmg, within a dose of 13.3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a coenzyme fraction of about 0,451 mass%, i.e. a quantity of said coenzyme fraction in the range from 50 to 70 mg, preferably 60mg, within a dose of 13.3g.
  • the food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same is in the form of tablets.
  • each tablet is so shaped and dimensioned that it allows said tablet to be easily swallowed.
  • said tablets are in such a form that one dosage includes a plurality of those tablets.
  • the tablets may be accommodated within a dosage receptacle which includes a number of those tablets. It is possible for the food composition to be in the form of small tablets or balls, and to keep same in a small tube, while the volume of the food composition taken by the consumer can be determined with respect to the volume of alcohol which is expected to be consumed.
  • the food composition or dietary supplementation may also be in a form similar to sugar-cubes, or might be in the form of cryopowder.
  • the food composition or dietary supplementation may be separated into separate subunits. It is possible to provide one unit, for example a capsule including the Vitamin C fraction, cysteine, riboflavin, succinic acid, fumaric acid and coenzyme QlO, whilst most of the dextrose fraction is kept in separate units, capsules, tablets or the like. It is possible to add further substances such as fruit juice extracts, curcuma, tannin, a powder of Panax notoginseng, and Vinca rosea in suitable amounts. Oolong tea, aloe vera and spiral water algae might also be added.
  • the food-composition or dietary supplementation may also be in the form of a liquid, in particular a sirup-type liquid. It is possible to provide the food composition in the appearance of a soft drink in a small bottle.
  • Glucose is rapidly oxidised in the cytosol of liver cells using the same cytosol NAD+ pool used by ethanol to be converted into acetaldehyde. Because the amount of cytosolic NAD+ is limited and can only constantly be reproduced from NADH+H much less acetaldehyde accumulates.
  • the second achievement is also believed to be achieved by the intake of a large dose of glucose.
  • Glucose augments the enzymatic activity of ADH as well as of ALDH.
  • a large glucose load occurs in the cytosol of liver cells then there is no possibility that the acetaldehyde reaches levels which could lead to inactivation of ALDH or to mitochondrial destruction.
  • Riboflavin will quickly be transformed to FMN, which together with coenzyme Qio is the determining substance for the speed of the reoxidation of NADH+H + to NAD + in the mitochondrial matrix.
  • Acetaldehyde needs NAD+ when it is metabolised to acetic acid.
  • NAD + is transformed into NADH+H + .
  • NADH+H + has to be re-transformed into NAD + to serve again for acetaldehyde decomposition.
  • coenzyme Qi 0 makes also sense because its level decreases in the human body with progressing age.
  • the activation of the Krebs (citrate) cycle is believed to be achieved by the inclusion of succinic acid and fumaric acid. Both substances activate the second half of the citrate cycle and thereby activate the aerobic oxidation process in mitochondria.
  • L-glutamine helps to speed up the mitochondria-cytosolic malate- asparate shuttle, which plays a key role in the course of intoxication by acetaldehyde. It also speeds up the succinate oxidation process by preventing oxalic and acetic inhibition of succinate dehydrogenase.
  • cysteine Ascorbic acid and also of L-glutamine.
  • Cysteine should provide a strong anti-oxidant effect as well as ascorbic acid.
  • the human body transforms cysteine to gluthatione which specially protects against the toxic effects of acetaldehyde. To reach an optimal level of gluthatione and to avoid cysteine being transformed to cystine, it is important to combine cysteine with glutamine and give twice as much ascorbic acid as cysteine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention is directed to a composition, in particular a food composition, or dietary supplementation which is active in respect to the support and/or the moderation of alcohol degradation process within the human body. The present invention particularly addresses the problem of rapid alcohol degradation i.e. alcohol metabolism as may occur in most people of Non-Caucasian type genetic structure. In this regard, an object of the present invention is to achieve solutions which provide a reduction in the physiological stress in connection with the consumption of alcohol, in particular for people with a predisposition towards rapid alcohol degradation. According to the present invention this object is attained by a food composition or dietary supplementation including the following substances: dextrose, Vitamin C, L-glutamine cysteine, riboflavin, succininc, acid, fumaric acid, niacin and coenzyme Q10, all substances in physiologically relevant doses in particular as disclosed. The composition is used for reducing alcohol induced liver cancer risc.

Description

COMPOSITION FOR REDUCING ALCOHOL INDUCED LIVER CANCER RISC
The present invention is directed to a composition, in particular a food composition, or dietary supplementation, which is active in respect to a reduction of alcohol or drug induced liver cancer rise. In this respect the invention is directed to a composition affecting the moderation of a drug, in particular alcohol degradation process within the human body.
In this regard, an object of the present invention is to achieve solutions which provide a reduction in the toxic effects or physiological stress in connection with the consumption of drugs, in particular alcohol, in particular for people with a predisposition towards rapid alcohol degradation and subsequent accumulation of acetaldehyde due to a genetic polymorphism of human acetaldehyde-dehydrogenase enzym.
According to the present invention this object is attained by a food composition, or dietary supplementation including the following substances:
dextrose, Vitamin C, L-glutamine cysteine, riboflavin, succinic acid, fumaric acid, coenzyme QlO, and niacin.
all substances in physiologically relevant doses.
With this particular food composition, or dietary supplementation it will become possible to reduce the activity, or to suppress the production of a particular alcohol dehydrogenase enzyme (ADH3), to slow down the production of acetaldehyde and the ethanol metabolism process and reduce the alcohol induced peak load on the human organism. Further the enzymatic activity of aldehyde dehydrogenase ALDH2 will be enhanced, so that the metabolisation of acetaldehyde will be supported.
There is considerable epidemic evidence that drinking alcoholic beverages is associated with increases risk for certain kinds of cancer including liver cancer. Ethanol taken into the body is eliminated by its oxidation mainly in the liver. Ethanol is first metabolised to acetaldehyde by alcohol dehydrogenase (ADH), and then acetaldehyde is further metabolised to acetic acid by aldehyde dehydrogenase (ALDH). The first metabolite of orally ingested alcohol, acetaldehyde, is suspected to play a pivotal role in the development of alcohol related cancers because of its established DNA damaging effects (single-strand and double-strand breaks) and carcinogenicity in laboratory animals. In fact, acetaldehyde can damage the culture hepatocytes and results in secondary hyperproliferation .
There are polymorphic isoforms of ALDH and class 2 ALDH (ALDH2), which has the lowest affinity constant (Km), is the most important enzyme for acetaldehyde oxidation. A mutant allele ALDH2*2, has a single point mutation (G- »A) in exon 12 of the active ALDH2*1 gene. This mutation is expected to result in a substitution of glutamic acid (GIu) at amino acid position 487 by lysine (Lys), acting in a dominant negative fashion. This mutation is confined to Orientals. Acetaldehyde oxidation is strikingly impaired in individuals with ALDH2*2 allele. ALDH2 deficiency is associated with increased the risk of cancer of the oral cavity, pharynx, larynx and esophagus.
Hepatitis viruses (HV), especially HVB and HVC, are known to increase the risk of liver cancer. Epidemiological surveys are considered to support that ALDH2 deficiency is associated with increased the risk of liver cancer of alcohol drinkers with or without hepatitis viruses. This supports the notion that acetaldehyde is closely involved in the carcinogenesis of hepatocytes in human alcohol drinkers. Our supplement mix accelerates the metabolism of alcohol and acetaldehyde. This mixture decreases the concentration of blood acetaldehyde after drinking. Therefore, our supplement is expected to decrease the risk of liver cancer for alcohol drinkers, especially those who have ALDH2*2 allele.
These particular effects help to reduce the peak load of critical substances on the human body, and further reduce a flushing syndrome, reduce the likelihood of headaches and also help to avoid or ease a hangover the day after.
The present invention particularly solves the problem of a long impact of an accumulation of acetaldehyde after rapid alcohol degradation i.e. alcohol metabolism as may occur in most people of Non-Caucasian type genetic structure.
The particular food composition or dietary supplementation is considered to be appropriate to reduce a peak of excess acetaldehyde entering the blood stream and is intended to lower the risk of damage to vital organs and functions of the human body, and in this connection also lowers the risk of liver cancer.
It is considered as evident that drinking alcoholic beverages is associated with increases risk for certain kinds of cancer including liver cancer . The association of alcohol consumption with increased risk for liver cancer is considered as beeing evident at least implicitly from epidemiological studies indicating that alcohol itself and/or its metabolite(s) has carcinogenic potency. Ethanol taken into the body is eliminated by its oxidation. Ethanol is first metabolised to acetaldehyde by alcohol dehydrogenase (ADH), and then acetaldehyde is further metabolised to acetic acid by aldehyde dehydrogenase (ALDH).
The niacin-fraction (Vitamin B3) included in the composition functions as nicotinamide adenine dinucleotide (NAD), which is effective towards a coenzyme to alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). This vitamin is provided to accelerate ethanol metabolism.
According to a particularly preferred embodiment, the composition also includes Pantotheic acid. Pantotheic acid functions as coenzyme A (CoA), which is considered necessary to metabolize acetic acid. Acetic acid is activated in conjugation with CoA to form acetyl-CoA, which is metabolized in TCA cycle. In enzymatical point of view, elimination of a product (acetic acid) is effective towards an acceleration of the metabolism of a substrate (acetaldehyde).
Preferably this food composition or supplements should be taken about 5 minutes prior to consumption of alcohol and in case of high alcohol consumption again whilst consuming alcohol. The mass of the food composition taken by the consumer should be in the range of about 70 to 120% of the mass of the alcohol included in the consumed drinks. A standard dose might include about 10. Og dextrose, 1.Og Vitamin C, 1.5g L-glutamine, 500mg cysteine, 40mg riboflavin, 100 mg succinic acid, 100 mg fumaric acid, 60mg coenzyme QlO, and about 10 mg Niacin (Vitamin B3). Preferably the relation of the components of the composition is oriented towards the above given relation. The overall dosage may be adapted to the body mass weight of the consumer.
The particular food composition, or dietary supplementation is intended to prevent too much acetaldehyde passing into the mitochondrial matrix and to suppress self- blockade of the enzymatic activity of ALDH and thus facilitate its the decomposition of acetaldehyde.
The physiological risks in connection with alcohol consumption may therefore be significantly reduced by the use of the food composition according to the present invention, as this food composition or dietary supplementation facilitates in a synergetic manner an early decrease of the level of acetaldehyde after drinking and simultaneously provides a protective effect in respect of the suppression of the generation of free radicals.
Said food composition or dietary supplementation is preferably in such a form, preferably as ingredients of a kind of aperitif, that it allows the food composition to be consumed within a restaurant or a bar prior to consuming alcoholic drinks. Preferably a dosage for a person with a body weight of about 80 kg includes a dextrose fraction of approx. 75%, wherein the said dosage may have an overall weight of about 10 to 15, preferably 13.3g. Such a dosage is to provide a considerable moderation in degrading about 18ml alcohol.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same, includes a dextrose fraction of about 75.2 mass%, i.e. a quantity of dextrose in the range from 7.2 to 12.8g, preferably 10.0 g within a dose of 13,3g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a Vitamin C fraction of about 7.5 mass% i.e a quantity of Vitamin C in the range from 0.78 to 1.18 g, preferably 1.Og, within a dose of 13.3g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a L-glutamine fraction of about 11.27 mass%, i.e. a quantity of said L-glutamine fraction in the range from 1.23 to 1.7 g, preferably 1.5g, within a dose of 13.3g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a cysteine fraction of about 3.76 mass%, i.e. a quantity of said cysteine fraction in the range from 460 to 540 mg, preferably 500mg, within a dose of 13.3g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a riboflavin fraction of about 0.30 mass% i.e. a quantity of said riboflavin in the range from 32 to 48 mg, preferably 40mg, within a dose of 13.3g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a succinic acid (Bernsteinsaure) fraction of about 0.752 mass%, i.e. a quantity of said succinic acid in the range from 90 to 1 10 mg, preferably lOOmg, within a dose of 133g. The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a fumaric acid (Fumarsaure) fraction of about 0.752 mass%, i.e. a quantity of said fumaric acid in the range from 90 to 110 mg, preferably lOOmg, within a dose of 13.3g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same includes a coenzyme fraction of about 0,451 mass%, i.e. a quantity of said coenzyme fraction in the range from 50 to 70 mg, preferably 60mg, within a dose of 13.3g.
The food composition or dietary supplementation is preferably constituted in a manner wherein a dosage of same is in the form of tablets. Preferably, each tablet is so shaped and dimensioned that it allows said tablet to be easily swallowed.
Preferably, said tablets are in such a form that one dosage includes a plurality of those tablets.
The tablets may be accommodated within a dosage receptacle which includes a number of those tablets. It is possible for the food composition to be in the form of small tablets or balls, and to keep same in a small tube, while the volume of the food composition taken by the consumer can be determined with respect to the volume of alcohol which is expected to be consumed.
The food composition or dietary supplementation may also be in a form similar to sugar-cubes, or might be in the form of cryopowder.
The food composition or dietary supplementation may be separated into separate subunits. It is possible to provide one unit, for example a capsule including the Vitamin C fraction, cysteine, riboflavin, succinic acid, fumaric acid and coenzyme QlO, whilst most of the dextrose fraction is kept in separate units, capsules, tablets or the like. It is possible to add further substances such as fruit juice extracts, curcuma, tannin, a powder of Panax notoginseng, and Vinca rosea in suitable amounts. Oolong tea, aloe vera and spiral water algae might also be added.
The food-composition or dietary supplementation may also be in the form of a liquid, in particular a sirup-type liquid. It is possible to provide the food composition in the appearance of a soft drink in a small bottle.
The particular food composition or dietary supplementation is considered to provide the following achievements:
1. Reduction of ethanol metabolism by slowing down the process of ethanol oxidation into acetaldehyde, to prevent accumulation of acetaldehyde in the first place.
2. Stimulation of the activity of ALDH and avoiding any blockade of its enzymatic activity.
3. Speeding up the reaction from acetaldehyde to acetic acid and the further decomposition in the citrate cycle.
4. Improving the levels of those anti-oxidants of the alcohol consumer, which specially protect against toxic effects of acetaldehyde.
The first achievement
is believed to be reached by the intake of a large dose of dextrose sugar (glucose). Glucose is rapidly oxidised in the cytosol of liver cells using the same cytosol NAD+ pool used by ethanol to be converted into acetaldehyde. Because the amount of cytosolic NAD+ is limited and can only constantly be reproduced from NADH+H much less acetaldehyde accumulates.
The second achievement is also believed to be achieved by the intake of a large dose of glucose. Glucose augments the enzymatic activity of ADH as well as of ALDH. When a large glucose load occurs in the cytosol of liver cells then there is no possibility that the acetaldehyde reaches levels which could lead to inactivation of ALDH or to mitochondrial destruction.
The third achievement is believed to be performed by
a) Accelerating the reoxidation from NADH+H+ to NAD+ by speeding up the transport of electrons through the inner mitochondrial membrane
b) Accelerating the Krebs cycle
It is believed to be achieved by the inclusion of coenzyme Qi0 and riboflavin. Riboflavin will quickly be transformed to FMN, which together with coenzyme Qio is the determining substance for the speed of the reoxidation of NADH+H+ to NAD+ in the mitochondrial matrix. Acetaldehyde needs NAD+ when it is metabolised to acetic acid. Within this reaction NAD+ is transformed into NADH+H+. Because the availability of NAD+ is limited in the mitochondrial matrix NADH+H+ has to be re-transformed into NAD+ to serve again for acetaldehyde decomposition. This reaction is only possible because FMN and coenzyme Qi o absorb the electrons of NADH+H+ and shuttle them through the mitochondrial membrane. The more FMN and coenzyme Qi0 are available, the more this process is speeded up and, because more NAD+ is available, the metabolism of acetaldehyde is accelerated.
The inclusion of coenzyme Qi0 also makes also sense because its level decreases in the human body with progressing age.
The activation of the Krebs (citrate) cycle is believed to be achieved by the inclusion of succinic acid and fumaric acid. Both substances activate the second half of the citrate cycle and thereby activate the aerobic oxidation process in mitochondria. L-glutamine helps to speed up the mitochondria-cytosolic malate- asparate shuttle, which plays a key role in the course of intoxication by acetaldehyde. It also speeds up the succinate oxidation process by preventing oxalic and acetic inhibition of succinate dehydrogenase. The fourth achievement,
the elevation of anti-oxidant levels, is believed to be achieved by the inclusion of cysteine, ascorbic acid and also of L-glutamine. Cysteine should provide a strong anti-oxidant effect as well as ascorbic acid. The human body transforms cysteine to gluthatione which specially protects against the toxic effects of acetaldehyde. To reach an optimal level of gluthatione and to avoid cysteine being transformed to cystine, it is important to combine cysteine with glutamine and give twice as much ascorbic acid as cysteine.
By taking the mentioned substances, it is expected that the level of acetaldehyde after drinking alcohol will be remarkably reduced and flushing symptoms at least diminished. The other known side-effects of acetaldehyde such as headaches and hangovers should also disappear.

Claims

1. Food composition, or dietary supplementation for reducing alcohol induced liver cancer rise by moderating a drug degradation process in respect to ethanol metabolism within the human body, including the following substances in physiologically relevant amount:
niacin (Vitamin B3), dextrose,
Vitamin C,
L-glutamine, cysteine, riboflavin, succinic acid, and/or fumaric acid, coenzyme QlO.
2. Food composition or dietary supplementation according to claim 1, wherein a dose of same has a weight of about 13.8g, said dose being configured in a manner which allows same to be consumed within a restaurant or a bar prior to the consumption of alcohol.
3. Food composition or dietary supplementation according to claim 1 or 2, wherein a dose of same includes a dextrose fraction of about 75.2 mass%.
4. Food composition or dietary supplementation according to at least one of claims 1 to 3, wherein a dose of same includes a Vitamin C fraction of about 7.5 mass%.
5. Food composition or dietary supplementation according to at least one of claims 1 to 4, wherein a dose of same includes a L-glutamine fraction of about 11.28 mass%.
6. Food composition or dietary supplementation according to at least one of claims 1 to 5, wherein a dose of same includes a cysteine fraction of about 3.76 mass%.
7. Food composition or dietary supplementation according to at least one of claims 1 to 6, wherein a dose of same includes a riboflavin fraction of about 0.3 mass%.
8. Food composition or dietary supplementation according to at least one of claims 1 to 7, wherein a dose of same includes a succinic acid fraction of about 0.752 mass%.
9. Food composition or dietary supplementation according to at least one of claims 1 to 8, wherein a dose of same includes a fumaric acid fraction of about 0.752 mass%.
10. Food composition or dietary supplementation according to at least one of claims 1 to 9, wherein a dose of same includes a coenzyme fraction of about 0.451 mass%.
11. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein same is in the form of tablets.
12. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein a dose of same includes a plurality of small tablets or capsules.
13. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein said tablets or capsules are contained in a dosage receptacle.
14. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein said composition is of a sugar-cube type form.
15. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein same is in the form of cryopowder.
16. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein same is in the form of a small drink unit.
17. Food composition or dietary supplementation according to at least one of claims 1 to 10, wherein same is in the form of a sirup.
18. Food composition, or dietary supplementation for reducing alcohol or drug induced liver cancer rise including niacin for affecting an alcohol degrading process in particular in respect to ethanol metabolism within the human body, substances, in particular substances mentioned above, providing the following effects within the human body:
- Reducing ethanol metabolism by slowing down the process of ethanol oxidation into acetaldehyde, to prevent accumulation of acetaldehyde in the first place;
- Stimulating the activity of ALDH and avoiding any blockade of its enzymatic activity;
- Speeding up the reaction from acetaldehyde to acetic acid and further decomposition in the citrate cycle;
Improving the levels of those anti-oxidants of the alcohol consumer which specially protect against toxic effects of acetaldehyde.
PCT/EP2005/009151 2005-07-29 2005-08-24 Composition for reducing alcohol induced liver cancer risk WO2007016953A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
JP2008523251A JP5371428B2 (en) 2005-07-29 2006-07-27 Composition for reducing alcohol metabolism and reducing the risk of alcohol-induced diseases
KR1020077028054A KR101562271B1 (en) 2005-07-29 2006-07-27 Compositions for alleviating alcohol metabolism and reducing the risk of alcohol-induced diseases
PCT/EP2006/007466 WO2007017139A1 (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
AU2006278823A AU2006278823B2 (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
EP06762860A EP1909600B1 (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
CA2611389A CA2611389C (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
ES06762860T ES2386460T3 (en) 2005-07-29 2006-07-27 Composition to moderate alcohol metabolism and to reduce the risk of alcohol-induced diseases
KR20137031344A KR101487848B1 (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
US11/997,127 US8580750B2 (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
DK06762860.2T DK1909600T3 (en) 2005-07-29 2006-07-27 Composition for moderation of alcohol metabolism and to reduce the risk of alcohol-caused diseases
PL06762860T PL1909600T3 (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
AT06762860T ATE554663T1 (en) 2005-07-29 2006-07-27 COMPOSITION FOR CONTROLLING ALCOHOL METABOLISM AND REDUCING THE RISK OF ALCOHOL-RELATED DISEASES
UAA200800602A UA94713C2 (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing risk of alcohol induced diseases
EA200800427A EA012753B1 (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
PT06762860T PT1909600E (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
SI200631337T SI1909600T1 (en) 2005-07-29 2006-07-27 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
HK08110628.1A HK1117709A1 (en) 2005-07-29 2008-09-24 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
HRP20120489TT HRP20120489T1 (en) 2005-07-29 2012-06-12 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
JP2013091972A JP5785581B2 (en) 2005-07-29 2013-04-25 Composition for reducing alcohol metabolism and reducing the risk of alcohol-induced diseases
US14/058,388 US9402849B2 (en) 2005-07-29 2013-10-21 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05016563 2005-07-29
EP05016563.8 2005-07-29

Publications (1)

Publication Number Publication Date
WO2007016953A1 true WO2007016953A1 (en) 2007-02-15

Family

ID=36021900

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2005/009151 WO2007016953A1 (en) 2005-07-29 2005-08-24 Composition for reducing alcohol induced liver cancer risk
PCT/EP2005/009153 WO2007016955A1 (en) 2005-07-29 2005-08-24 Alcohol metabolism moderating composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/009153 WO2007016955A1 (en) 2005-07-29 2005-08-24 Alcohol metabolism moderating composition

Country Status (1)

Country Link
WO (2) WO2007016953A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057905A1 (en) * 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
WO2012095509A1 (en) * 2011-01-14 2012-07-19 Tima Foundation Composition for accelerating alcohol metabolism and for reducing the risk of alcohol induced diseases
CN102946898A (en) * 2010-06-19 2013-02-27 天野酶株式会社 Agent for reducing acetaldehyde in oral cavity
WO2013078371A2 (en) 2011-11-22 2013-05-30 The Johns Hopkins University Methods and compositions for reducing alcohol toxicity
WO2016016391A1 (en) * 2014-07-30 2016-02-04 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Agents for use in treating liver and pancreatic cancer
US10143669B2 (en) * 2015-01-23 2018-12-04 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids in cancer prevention
CN114891808A (en) * 2022-06-21 2022-08-12 珠海丽凡达生物技术有限公司 mRNA molecule for encoding ALDH2 polypeptide, application and mRNA medicament

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017212113A1 (en) * 2016-06-06 2017-12-14 Catapult Cat Oy Combination of l-cysteine, ascorbic acid and vitamin b3 for treating hangover

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2029220A (en) * 1978-09-04 1980-03-19 Otsuka Pharma Co Ltd Amino acid solutions for patients with cancers
RU2012350C1 (en) * 1993-05-17 1994-05-15 Александр Михайлович Шепеленко Agent for removing alcohol intoxication
EP0652012A1 (en) * 1989-03-27 1995-05-10 Albert Naito Combination of sugars with animo acids and other drugs
FR2748935A1 (en) * 1996-05-23 1997-11-28 Clergeaud Jean Composition to lessen alcohol passing into the bloodstream
WO2001085178A1 (en) * 2000-05-08 2001-11-15 N.V. Nutricia Nutritional preparation comprising ribose and folic acid and medical use thereof
US20020006910A1 (en) * 2000-05-18 2002-01-17 Dmitri Miasnikov Means for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome and a method for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome by using this means
EP1195159A1 (en) * 2000-10-09 2002-04-10 Rath, Matthias, Dr. med. Therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer
WO2003006073A1 (en) * 2001-07-10 2003-01-23 Penam Investments Pty Ltd A composition and uses therefor for combating hangover
EP1304046A1 (en) * 2001-10-18 2003-04-23 LOTTE CONFECTIONERY CO., Ltd. Theobromine with an anti-carcinogenic activity
WO2004037018A1 (en) * 2002-10-23 2004-05-06 Quercegen Holdings Llc Composition for enhancing physical performance
RU2240789C1 (en) * 2003-12-24 2004-11-27 Закрытое акционерное общество "НПО ПЦ БИОФИЗИКА" Agent eliciting hepatoprotective property, for reducing alcoholic intoxication, prophylaxis and elimination of alcoholic intoxication and alcohol withdrawal syndrome
DE10326822A1 (en) * 2003-06-11 2005-01-05 Herzpharma Vita-Check Diagnosegeräte GmbH Dietary supplement, e.g. for increasing general performance, concentration and endurance, comprises NADH, L-carnitine, coenzyme Q10, L-carnosine, succinic acid, ascorbic acid and bioflavonoids
WO2005077464A1 (en) * 2004-02-17 2005-08-25 Matuschka-Greinffenclau Markus Alcohol metabolism moderating composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1058914A (en) * 1991-03-16 1992-02-26 肖宏生 Multifunctional oral liquor containing spirits liquid

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2029220A (en) * 1978-09-04 1980-03-19 Otsuka Pharma Co Ltd Amino acid solutions for patients with cancers
EP0652012A1 (en) * 1989-03-27 1995-05-10 Albert Naito Combination of sugars with animo acids and other drugs
RU2012350C1 (en) * 1993-05-17 1994-05-15 Александр Михайлович Шепеленко Agent for removing alcohol intoxication
FR2748935A1 (en) * 1996-05-23 1997-11-28 Clergeaud Jean Composition to lessen alcohol passing into the bloodstream
WO2001085178A1 (en) * 2000-05-08 2001-11-15 N.V. Nutricia Nutritional preparation comprising ribose and folic acid and medical use thereof
US20020006910A1 (en) * 2000-05-18 2002-01-17 Dmitri Miasnikov Means for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome and a method for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome by using this means
EP1195159A1 (en) * 2000-10-09 2002-04-10 Rath, Matthias, Dr. med. Therapeutic combination of ascorbate with lysine or arginine for prevention and treatment of cancer
WO2003006073A1 (en) * 2001-07-10 2003-01-23 Penam Investments Pty Ltd A composition and uses therefor for combating hangover
EP1304046A1 (en) * 2001-10-18 2003-04-23 LOTTE CONFECTIONERY CO., Ltd. Theobromine with an anti-carcinogenic activity
WO2004037018A1 (en) * 2002-10-23 2004-05-06 Quercegen Holdings Llc Composition for enhancing physical performance
DE10326822A1 (en) * 2003-06-11 2005-01-05 Herzpharma Vita-Check Diagnosegeräte GmbH Dietary supplement, e.g. for increasing general performance, concentration and endurance, comprises NADH, L-carnitine, coenzyme Q10, L-carnosine, succinic acid, ascorbic acid and bioflavonoids
RU2240789C1 (en) * 2003-12-24 2004-11-27 Закрытое акционерное общество "НПО ПЦ БИОФИЗИКА" Agent eliciting hepatoprotective property, for reducing alcoholic intoxication, prophylaxis and elimination of alcoholic intoxication and alcohol withdrawal syndrome
WO2005077464A1 (en) * 2004-02-17 2005-08-25 Matuschka-Greinffenclau Markus Alcohol metabolism moderating composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199505, Derwent World Patents Index; Class B05, AN 1995-034579, XP002373928 *
DATABASE WPI Section Ch Week 200506, Derwent World Patents Index; Class B05, AN 2005-055600, XP002373159 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057905A1 (en) * 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
WO2009062910A1 (en) * 2007-11-12 2009-05-22 Tima Foundation Composition for moderating triglyceride and cholesterol levels
CN102946898A (en) * 2010-06-19 2013-02-27 天野酶株式会社 Agent for reducing acetaldehyde in oral cavity
WO2012095509A1 (en) * 2011-01-14 2012-07-19 Tima Foundation Composition for accelerating alcohol metabolism and for reducing the risk of alcohol induced diseases
EP2782583A4 (en) * 2011-11-22 2016-04-13 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR REDUCING TOXICITY OF ALCOHOL
KR20140106549A (en) * 2011-11-22 2014-09-03 더 존스 홉킨스 유니버시티 Methods and compositions for reducing alcohol toxicity
CN104520311A (en) * 2011-11-22 2015-04-15 约翰霍普金斯大学 Methods and compositions for reducing alcohol toxicity
WO2013078371A2 (en) 2011-11-22 2013-05-30 The Johns Hopkins University Methods and compositions for reducing alcohol toxicity
CN104520311B (en) * 2011-11-22 2018-03-13 约翰霍普金斯大学 For reducing the method and composition of Alcoholism
KR102002147B1 (en) 2011-11-22 2019-07-19 더 존스 홉킨스 유니버시티 Methods and compositions for reducing alcohol toxicity
WO2016016391A1 (en) * 2014-07-30 2016-02-04 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Agents for use in treating liver and pancreatic cancer
US10143669B2 (en) * 2015-01-23 2018-12-04 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids in cancer prevention
US10231941B2 (en) 2015-01-23 2019-03-19 Temple University—Of The Commonwealth System of Higher Educaton Use of short chain fatty acids in cancer prevention
AU2019201799B2 (en) * 2015-01-23 2020-10-15 Helena M.G.P.V. Reis Use of short chain fatty acids in cancer prevention
US11963938B2 (en) 2015-01-23 2024-04-23 Temple University-Of The Commonwealth System Of Higher Education Use of short chain fatty acids in cancer prevention
CN114891808A (en) * 2022-06-21 2022-08-12 珠海丽凡达生物技术有限公司 mRNA molecule for encoding ALDH2 polypeptide, application and mRNA medicament
CN114891808B (en) * 2022-06-21 2023-10-27 珠海丽凡达生物技术有限公司 mRNA molecule encoding ALDH2 polypeptide, application and mRNA medicament

Also Published As

Publication number Publication date
WO2007016955A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
US9402849B2 (en) Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
AU2005211936B2 (en) Alcohol metabolism moderating composition
Dasgupta Alcohol and its biomarkers: clinical aspects and laboratory determination
JP2007522254A6 (en) Alcohol metabolism regulating composition
WO2007016953A1 (en) Composition for reducing alcohol induced liver cancer risk
WO2007016949A1 (en) Composition for reducing the risc of alcohol induced neuropathy
CN114246941A (en) A kind of composition with preventing hangover, hangover and liver protection and application thereof
WO2012095509A1 (en) Composition for accelerating alcohol metabolism and for reducing the risk of alcohol induced diseases
WO2007016954A1 (en) Composition for reducing drug or alcohol induced breast cancer risk
WO2007016950A1 (en) Composition for reducing the risk of alcohol induced neurodegenerative disease
WO2007016952A1 (en) Composition for reducing the risk of alcohol induced esophagenal and oropharyngolaryngeal cancer
CN109562090A (en) For treating the composition of L- cysteine acid, ascorbic acid and the vitamin B3 be still drank after a night
WO2007016951A1 (en) Composition for reducing the risc of alcohol induced pancreatic cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05775870

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载